FARN vs. GNS, ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, CIR, and 4BB
Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy vs.
Faron Pharmaceuticals Oy (LON:FARN) and Genus (LON:GNS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Genus has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
In the previous week, Genus had 3 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 3 mentions for Genus and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.92 beat Genus' score of 0.30 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.
10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 77.8% of Genus shares are owned by institutional investors. 31.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 0.8% of Genus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Genus has a consensus target price of GBX 2,150, suggesting a potential upside of 11.89%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than Faron Pharmaceuticals Oy.
Genus has a net margin of 1.18% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Genus' return on equity of 1.41% beat Faron Pharmaceuticals Oy's return on equity.
Genus received 36 more outperform votes than Faron Pharmaceuticals Oy when rated by MarketBeat users. However, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 70.60% of users gave Genus an outperform vote.
Summary
Genus beats Faron Pharmaceuticals Oy on 14 of the 17 factors compared between the two stocks.
Get Faron Pharmaceuticals Oy News Delivered to You Automatically
Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Faron Pharmaceuticals Oy Competitors List
Related Companies and Tools
This page (LON:FARN) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy FARN Stock Free FARN Stock Alerts